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Partially Protects Dystrophic Skeletal Muscle
Hannah R. Spaulding1, Christopher G. Ballmann2, John C. Quindry2, Joshua T. Selsby1*
1 Department of Animal Science, Iowa State University, Ames, IA, United States of America, 2 School of
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Abstract
Duchenne muscular dystrophy (DMD) results from a genetic lesion in the dystrophin gene
and leads to progressive muscle damage. PGC-1α pathway activation improves muscle
function and decreases histopathological injury. We hypothesized that mild disease found in
the limb muscles of mdx mice may be responsive to quercetin-mediated protection of dystro-
phic muscle via PGC-1α pathway activation. To test this hypothesis muscle function was
measured in the soleus and EDL from 14 month old C57, mdx, and mdx mice treated with
quercetin (mdxQ; 0.2% dietary enrichment) for 12 months. Quercetin reversed 50% of dis-
ease-related losses in specific tension and partially preserved fatigue resistance in the
soleus. Specific tension and resistance to contraction-induced injury in the EDL were not
protected by quercetin. Given some functional gain in the soleus it was probed with histolog-
ical and biochemical approaches, however, in dystrophic muscle histopathological out-
comes were not improved by quercetin and suppressed PGC-1α pathway activation was
not increased. Similar to results in the diaphragm from these mice, these data suggest that
the benefits conferred to dystrophic muscle following 12 months of quercetin enrichment
were underwhelming. Spontaneous activity at the end of the treatment period was greater in
mdxQ compared to mdx indicating that quercetin fed mice were more active in addition to
engaging in more vigorous activity. Hence, modest preservation of muscle function (specific
tension) and elevated spontaneous physical activity largely in the absence of tissue damage
in mdxQ suggests dietary quercetin may mediate protection.
Introduction
Duchenne muscular dystrophy (DMD) is caused by the absence of the dystrophin protein,
which acts to transmit force between cytoskeleton and extracellular matrix via the dystrophin
glycoprotein complex (DGC) [1, 2]. The absence of dystrophin results in cellular dysfunction
including decreased calcium homeostasis, increased necrosis, and disruption of DGC along
with other secondary effects producing whole muscle dysfunction. Utrophin, a dystrophin-like
protein, participates in DGC formation, stability, and function in the absence of dystrophin
[3, 4], hence utrophin upregulation remains an area of intense research interest [5–8]. Utro-
phin transcription can be driven by the exercise-sensitive PGC-1α pathway [9], however,
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attempts to use various exercise modalities as interventions for DMD have been met with
mixed results [10–13]. Direct activation of the PGC-1α pathway using transgenic and gene
transfer approaches yields consistently positive results using both prevention and rescue para-
digms [14–18]. Under these conditions PGC-1α pathway activation led to increased muscle
function, decreased muscle damage, increased utrophin abundance and a physiologic and
metabolic type I shift in PGC-1α over-expressing dystrophic muscle compared to control mus-
cle [14–18].
Given the emerging success of PGC-1α pathway activation for treating dystrophic pathol-
ogy we next searched for PGC-1α activators that already had FDA approval or were freely
available to minimize time needed to impact patients. Quercetin, a flavonoid with antioxidant
and anti-inflammatory properties [19], drives the PGC-1α pathway through SIRT1 deacetylase
[20, 21] or AMPK activity [22]. We found previously that six months of dietary quercetin
enrichment decreased histopathology in diaphragms [23] and hearts [24] from dystrophic
mice. In a follow up experiment we found that 12 months of quercetin dietary enrichment
transiently protected dystrophic diaphragms and respiratory function though a developed
quercetin insensitivity ultimately minimized therapeutic benefits [25]. Given that limb muscles
from mdx mice suffer a more mild disease than diaphragms we reasoned that quercetin
may continue to protect limb muscle from progressive disease and, therefore, that quercetin
would have a role as a therapeutic intervention early in the disease process and would be most
efficacious in the youngest DMD patients. We hypothesized that muscle function would be
improved and histological injury would be decreased in dystrophic soleus and extensor digi-
torum longus (EDL) following 12 months of dietary quercetin enrichment compared to mus-
cles taken from mice maintained on a control diet.
Methods
Ethical Approval and Animal Treatments
The Institutional Animal Care and Use Committee at Auburn University reviewed and
approved all procedures utilized in this work. Previous work, including a detailed study design,
has been previously published [25]. Briefly, eight male C57 mice and 16 male mdx mice (Jack-
son Laboratories) were acclimated for one week prior to the beginning of the experiments.
At 2 months of age a standard AIN93 diet (Bioserv, Flemington, NJ) was provided for C57
mice (n = 8) and control mdx mice (n = 8), while treated mdx mice received an AIN93 diet
supplemented with 0.2% quercetin (n = 8) for 12 months. Both water and food were available
ad libitum. Throughout the study period animal food, water, bedding, general health, and envi-
ronmental conditions were checked twice daily by a combination of research and vivarium
staff. Over the course of this longitudinal investigation one mouse from each group was
identified as severely ill (monitored criteria included: physical appearance, weight loss, and
behavior). To minimize suffering animals were euthanized via CO2 inhalation followed by
exsanguination consistent with our IACUC protocol. Changes in body weight throughout the
study period have been previously reported as have average daily food consumption (3.9 g/day)
and resultant daily quercetin exposure (204 mg/kg/day) [25]. At 14 months of age, activity
was measured using an ethiological approach. Soleus and EDL in vitro muscle function were
assessed at the Physiological Assessment Core of the Wellstone Muscular Dystrophy Co-
operative Center at the University of Pennsylvania. Prior to in vitro function all animals were
assigned new numbers to establish blinded data collection and further preserve blinded con-
ditions upon distribution of tissues for subsequent analyses. Sample numbers and animal
groups were revealed prior to biochemical analysis for properly controlled experiments. Due
to the length of this study several animals did not reach 14 months of age or tissues were
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unusable for some measures, thus number/group is identified for all measurements in the fig-
ure legends.
Animal Activity
At 14 months of age, activity was recorded for 10 consecutive minutes in conscious mice and
were averaged over two observation periods for occurrences of sitting, grooming, eating/
drinking, socializing, standing, walking, wall pacing, running, and jumping. This technique
represents a species-specific ethogram (repertoire of discrete animal activities) using the “0–1
recording” method, which has been applied across many species. When an observed mouse
performed a particular activity (sitting, walking, etc.) it was recorded as 1. Activity counts were
performed on two occasions by two investigators and activity recordings were performed
every 15 seconds for 10 minutes and collectively equaled 40 activity time periods. Twenty total
minutes of activity were recorded for the two sessions and final counts were averaged from
scores generated by the two blinded observers. Activity counts were performed at a common
time at the end of the photo light and photo dark cycles [26].
Tissue Collection and Muscle Function
After 12 months of treatment, mice were sedated to a surgical level of anesthesia using a keta-
mine/xylazine cocktail at the Physiological Assessment Core of the Wellstone Muscular Dys-
trophy Cooperative Center at the University of Pennsylvania (now housed at the University of
Florida). Upon sedation, soleus and EDL muscles were removed from each animal and used
for measures of muscle function. In vitro muscle function was measured using standard tech-
niques as has been done previously [27–29]. Briefly, the tetanic force was determined in the
EDL and soleus using stimulation of 120 Hz and 100 Hz, respectively. To determine fatigue
resistance the soleus was stimulated for 10 minutes with one contraction/sec (100 Hz for 330
msec with 200 μsec pulse). To determine resistance to contraction-induced injury the EDL
was given a series of five lengthening contractions (500 msec at 80 hz followed by 10% beyond
Lo for 20 msec). To determine fatigue resistance and resistance to contraction induced injury
data are expressed relative to peak force produced during the first contraction. Specific tension
and cross sectional area were calculated using standard equations [30]. As there were changes
in soleus muscle function suggestive of a therapeutic effect tissues were examined with histo-
logical and biochemical approaches. Following the fatigue test the soleus was frozen in melting
isopentane and used for histological measures while the contralateral soleus was snap frozen
upon removal and used for biochemical measures.
Histological Analyses
Muscle injury and fibrosis were measured as recently described [25]. Briefly, 10 μm sections
were cut and stained with either hematoxylin and eosin (H&E) or Masson’s Trichrome
(KTMTR, American MasterTech, Lodi, CA). H&E and trichrome stained slides were imaged
with an inverted DMI3000 B microscope and QICAM MicroPublisher 5.0 (MP5.0-RTV-CLR-
10, QIMAGING) camera using QCapture software. Trained, blinded technicians took 3–5
images at 10x magnification for each soleus section. Overlapping images allowed for recon-
struction of the entire muscle cross section using the Photoshop merge option (Adobe). H&E
sections were then analyzed by these technicians using Open Lab (Improvision) to quantify 1)
total number of muscle cells, 2) central nucleation, 3) extracellular nuclei, 4) necrotic area, and
5) total contractile area (area of the section comprised of muscle fibers). Trichrome staining
was used to quantify areas of fibrosis.
Quercetin Partially Restores Specific Tension in the Dystrophic Soleus
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Immunohistochemistry was utilized to confirm fibrosis findings and measure fiber area dis-
tribution. To measure fibrosis and fiber area distribution anti-fibronectin (Sigma, St. Louis,
MO) and anti-laminin (1:100, Thermo Scientific, Waltham, MA) primary antibodies were
applied to the samples at 4˚C overnight, respectively. At room temperature, sections were
exposed to donkey anti-rabbit rhodamine secondary antibody (1:200, Millipore, Billerica, MA)
for 1 hour. 3–5 non-overlapping images were taken with a QICAM 12-bit Mono Fast 1394
Cooled (QIC-F-M-12-C, QIMAGING) camera at 10x magnification attached to the Leica
microscope under blinded conditions.
qPCR
Measurement of transcript abundance was performed in the soleus employing Fluidigm tech-
nology as we have done previously [25]. Our complete list of primer pairs has also been previ-
ously published. Briefly, mRNA was isolated using TriZol (ThermoScientific) and reverse
transcribed to cDNA using QuantiTect Reverse Transcriptase Kit (Qiagen) as described by the
manufacture, but random hexamers (IDT PreMade Primers) were substituted for the RT
Primer Mix (Qiagen). cDNA was further prepared as suggested by Fluidigm then loaded onto
a 96x96 Fluidigm chip.
Western Blot
Measurement of relative protein abundance was performed as previously described. Briefly,
200 μl of whole muscle buffer (10mM Sodium Phosphate buffer, pH 7.0, 2% SDS) was added
to powdered soleus tissue and homogenized. Once homogenized, samples were spun at 20,000
RCF for 15 minutes and supernatant containing the protein was collected for western blotting.
Protein concentration was measured using Pierce BCA Protein Assay Kit (ThermoScientific,
23225) and diluted with 2x Laemmli buffer. Once diluted, samples were heated for 5 minutes
at 95˚C. Thirty micrograms of protein were separate by mass using 4–20% gradient gels
(Lonza). Separation was run at 60 volts for 20 minutes followed by 120 volts for 60 minutes,
then transferred for 60 minutes at 100 volts onto a nitrocellulose membrane. Membranes were
probed for the following antibodies overnight at 4˚C then incubated for 1 hour with anti-rab-
bit secondary: phosphorylated (p-) AMPKα (thr172) (P 1:500, S 1:2000, Cell Signaling), SIRT1
(P 1:500, S 1:2000, Millipore), Histone 3 Lysine 9 Acetylation (H3K9ac) (P 1:1000, S 1:5000 in
0% milk, Cell Signaling), ERRα (P 1:1000, S 1:2000), TFAM (P 1:375 in 1% milk, S 1:1000 in
0% milk), Cytochrome C (P 1:1000, S 1:2000), SDHA (P 1:500, S 1:2000), VDAC (P 1:300, S
1:2000).
Statistics
All data were assessed using one-way ANOVA with a Newman-Keuls post-hoc test to assess
significance of p<0.05. Unless otherwise noted, data are shown as mean ± SEM.
Results
To determine the extent to which quercetin decreased dystrophic injury mdx mice were
treated with a 0.2% quercetin enriched diet or maintained on a control diet from 2–14 months
of age. We have previously reported detailed food consumption and growth data [25]. In brief,
animal growth was largely similar between groups though the mdxQ group was statistically
smaller than the mdx group at the conclusion of the investigation (C57–44.07 ± 2.13 g, mdx–
56.57 ± 2.30 g, mdxQ– 38.07 ± 2.35 g). In the soleus, dystrophin-deficiency caused a 40%
increase in absolute muscle mass regardless of treatment (Table 1). Relative muscle mass was
Quercetin Partially Restores Specific Tension in the Dystrophic Soleus
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nearly doubled in mdx compared to C57 and mdxQ was 11% greater (p<0.05) than mdx
(Table 1). In the EDL, absolute mass was 30 and 13% greater in mdx compared to C57 and
mdxQ, respectively, and mdxQ was 20% greater than C57 (Table 1). Relative EDL mass in dys-
trophic mice was increased by 60% compared to C57 (Table 1). Data for all measures is
included in S1 Table.
In vitro function
Tetanic force was similar between groups in the soleus. Specific tension, however, was
decreased by 40% in mdx compared to C57. Importantly, dietary quercetin enrichment attenu-
ated approximately 50% of this loss (Fig 1). Following a fatigue protocol, the percent of initial
force produced by the mdx soleus was decreased by 50% compared to C57. The addition of
quercetin appeared to attenuate this loss but this numerical difference was not statistically sig-
nificant from the other treatments (Fig 1C).
Table 1. Soleus and EDL muscle weights and function. * indicates significantly different from C57; # indicates significantly different from mdx. C57
(n = 6–7) mdx (n = 6) mdxQ (n = 5–6).
Soleus EDL
C57 mdx mdxQ C57 Mdx mdxQ
Mass (mg) 11.39 ± 0.17 17.61 ± 0.54 * 15.96 ± 1.08 * 12.73 ± 0.31 18.65 ± 0.67 * 16.30 ± 0.76 *#
Relative Mass (mg/g) 0.25 ± 0.01 0.45 ± 0.01 * 0.49 ± 0.02 *# 0.28 ± 0.01 0.47 ± 0.01 * 0.47 ± 0.03 *
Tetanic Force (mN) 224.7 ± 8.1 209.6 ± 21.5 252.9 ± 8.8 506.8 ± 13.7 461.1 ± 33.4 451.2 ± 13.0
doi:10.1371/journal.pone.0168293.t001
Fig 1. Soleus and EDL muscle function at 14 months of age. A) Specific tension measured in the soleus and B) in the EDL. C) The
soleus was then subjected to a fatigue test where it was stimulated once per second for 10 minutes. Force was normalized to force
produced in the first contraction. D) The relative force produced in the final contraction is shown. Relative force produced in the final
contraction was significantly less in mdx than C57. E) The EDL was subjected to a series of five eccentric contractions and peak force
normalized to peak force generated in the first contraction. * indicates significantly different from C57; # indicates significantly different
from mdx. C57 (n = 7) mdx (n = 6) mdxQ (n = 6).
doi:10.1371/journal.pone.0168293.g001
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Consistent with the soleus muscle, tetanic tension in the EDL was similar between groups
(Table 1). Specific tension was decreased by 36% in mdx and mdxQ groups compared to C57
(Fig 1B). In addition, dietary quercetin failed to provide protection from eccentric injury in
the EDL as the percent decline was similar in mdx and mdxQ and considerably less than C57
for each contraction (Fig 1E).
Animal activity was assessed by counts of sedentary and active behaviors during 15 second
sampling windows averaged over two 10 minute observation periods. For the sitting/standing
metrics, mdx mice were 35% more stationary than C57 and mdxQ was less stationary than
both C57 and mdx mice by 65% and 74%, respectively (Fig 2A). Total activity followed a simi-
lar pattern such that mdx were 47% less active than C57 whereas mdxQ were 2-fold more
active than C57 (Fig 2B).
Histopathology
Given that improved specific tension and fatigue resistance in the soleus provided some lim-
ited optimism for a successful intervention histological and biochemical studies were pursued.
The quantity of extracellular nuclei was increased by 4-fold and the percent of cells with a cen-
tralized nucleus was increased by 15-fold in dystrophic muscle compared to healthy muscle
and both measures were resistant to quercetin (Fig 3A–3F). Consistent with disease-related
injury the total contractile area was decreased 20% in mdx and mdxQ mice compared to C57
due to an accumulation of non-contractile material in the whole muscle cross-section (Fig
3G). Fibrotic tissue in the soleus of mdx mice measured via trichrome staining was 3.6-fold
higher while mdxQ mice were 4-fold higher than C57. In addition, trichrome staining revealed
that fibrosis in mdxQ increased by 12.5% compared to mdx (Fig 4A–4D). To verify these
changes we also assessed relative fibronectin abundance using an immunohistochemical
approach. We found that fibronectin was 9.0-fold higher in both mdx and mdxQ compared to
C57 and importantly, that mdx and mdxQ were similar between groups (Fig 5A–5D).
Lastly, we also measured fiber area distribution (Fig 6A–6D). We found that at 14 months
of age mean fiber area was similar between groups, however, the variance coefficient was 40%
higher in dystrophic muscle compared to healthy muscle (Fig 6E and 6F). Further, we found
that dystrophic muscle had a greater frequency of smaller diameter fibers and a smaller fre-
quency of larger diameter fibers compared to healthy muscle (Fig 6G). While dystrophic mus-
cle tended to have a greater frequency of very large fibers (>3000 μm) this observation was not
statistically significant from C57 (Fig 6D).
Biochemistry
We also assessed the impact of dystrophin deficiency on alterations in transcript expression
and the degree to which these were corrected by dietary quercetin enrichment (Table 2). Our
findings largely suggest that following 12 months of quercetin treatment transcript expression
was similar between mdx and mdxQ, however, numerous differences between dystrophic and
healthy muscle were noted. Specifically, metabolic transcripts were significantly decreased in
mdx mice compared to C57 as were transcripts related to mitochondrial biogenesis, redox bal-
ance, and cellular stability.
Lastly, we evaluated the pathway driven by quercetin (Fig 7). SIRT1 promotes PGC-1α
pathway activity [31–33], thus protein abundance of SIRT1 was measured and was 20% higher
in dystrophic muscle regardless of treatment compared to healthy muscle. In contrast, SIRT1
activity was lower in dystrophic muscle as histone 3 lysine 9 acetylation (H3K9ac) was 80%
higher in dystrophic muscle compared to control. Due to the deacetylase activity of active
SIRT1 increased H3K9ac is indicative of decreased SIRT1 activity. Downstream pathway
Quercetin Partially Restores Specific Tension in the Dystrophic Soleus
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components and end products of the PGC-1α pathway were similar between all groups. Due
to the potential function of quercetin as an AMPK activator [32, 34, 35], pAMPK T172 was
measured to assess AMPK activity. We found that AMPK activity was lower by more than 40%
in dystrophic muscle compared to control, and independent of feeding treatment.
Discussion
Duchenne muscular dystrophy is a muscle wasting disease that leads to progressive deteriora-
tion of muscle function and muscle health. Muscle atrophy and increased muscle injury nega-
tively impact motor function and eventually lead to death from cardiac or respiratory failure.
Protection of muscle from secondary effects of dystrophin deficiency such as inflammation,
metabolic dysfunction and free radical injury while simultaneously driving utrophin expres-
sion and mitochondrial biogenesis may slow disease progression and prolong muscle function.
Up regulation of PGC-1α in dystrophic muscle is well recognized to maintain muscle function,
Fig 2. Animal activity was increased by dietary quercetin enrichment. At the conclusion of the investigation animal
behavior was quantified using an ethological approach where a 10 minute observation period was divided into 15 second
blocks. A) The number of time blocks spent sitting or exhibiting sedentary behavior was quantified. B) We also quantified
the number of active behaviors. * indicates significantly different from C57; # indicates significantly different from mdx.
C57 (n = 7) mdx (n = 7) mdxQ (n = 6).
doi:10.1371/journal.pone.0168293.g002
Fig 3. Dystrophin deficiency causes histological injury that is not corrected by quercetin. A-C) Representative images from H&E-
stained, reconstructed soleus muscle cross sections. E) Extra cellular nuclei, F) centralized nuclei, and G) total contractile area were
calculated. * indicates significantly different from C57. Width of black bar represents 250 microns. C57 (n = 7) mdx (n = 6) mdxQ (n = 6).
doi:10.1371/journal.pone.0168293.g003
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decrease histological damage and increase utrophin protein abundance and localization [14–
18]. Currently needed is a pragmatic strategy to translate this mechanistic understanding into
clinical practice. As such, quercetin is a promising therapeutic supplement that exhibits both
antioxidant and anti-inflammatory properties and also drives mitochondrial biogenesis and
utrophin upregulation through PGC-1α activation. Supporting a rationale for clinical applica-
bility, quercetin is commonly sold as an over-the-counter supplement and is readily available
to the DMD community. Experimental evidence to support this postulate is derived from an
initial investigation where we found that a 6 month dietary intervention with quercetin
decreased histological injury in the dystrophic diaphragm [23] and heart [24]. In a subsequent
12-month study the beneficial effects following six months of treatment were recapitulated
[25]. These effects appeared to be transient, however, in that control diaphragms from dystro-
phic mice were functionally, histologically, and biochemically indistinguishable from querce-
tin-treated diaphragms by the end of the study period. We hypothesized that advanced disease
progression in the diaphragm may limit the therapeutic potential of quercetin and that the
milder phenotype found in dystrophic limb muscles would be a more amenable intracellular
environment to support the therapeutic effects of quercetin.
Similar to our previous findings in diaphragms [25] from the same animals used herein,
most outcomes examined at the end of the treatment period were not responsive to the querce-
tin intervention. Of note, dietary quercetin consumption was associated with prevention of
approximately 50% of the disease-related losses in specific tension and fatigue resistance in
the soleus. Improved specific tension in the soleus is surprising considering histological
Fig 4. Dystrophin deficiency increased muscle fibrosis. A-C) Representative images from trichrome-
stained, reconstructed soleus cross sections. D) Total fibrotic area was calculated by quantifying the blue
staining material in the entire muscle cross section. * indicates significantly different from C57. Width of black
bar represents 250 microns. C57 (n = 7) mdx (n = 6) mdxQ (n = 6).
doi:10.1371/journal.pone.0168293.g004
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parameters were not improved by dietary quercetin enrichment. Hence, muscle function was
improved in quercetin-treated mdx mice compared to control mice despite similar degrees of
muscle damage/unit cross sectional area. We encourage future studies intended to improve
clarity regarding the broad therapeutic effects of this strategy.
While these functional benefits are cause for limited enthusiasm our biochemical and histo-
logical findings require caution. On the whole, transcript expression was similar between
treated and untreated mdx mice and cellular functions probed in this investigation were
largely suppressed compared to C57. Published studies indicate that quercetin drives the PGC-
1α pathway through the deacetylase activity of SIRT1 [32, 36, 37] such that SIRT1 deacetylates
PGC-1α and ultimately leads to mitochondrial biogenesis, increased utrophin abundance, a
shift toward more oxidative fiber types, and decreased disease severity [14–18]. We previously
noted quercetin insensitivity in diaphragm tissues marked by increased SIRT1 protein abun-
dance coupled with impaired SIRT1 function [25]. In this investigation a similar mechanism
is apparent despite continued quercetin supplementation. We proposed previously that
decreased ATP content found in dystrophic muscle may be part of that mechanism by limiting
the potential of quercetin to increase SIRT1 activity via a blunted ATP/cAMP/pSIRT1 path-
way. Alternatively, we speculate that the lower abundance of NAD+ in dystrophic muscle [38],
a cofactor of SIRT1 activation [39], may also limit the capacity of quercetin to drive SIRT1
activity. Intriguingly, in a short-term investigation, supplementation with nicotinamide ribo-
side to augment the muscle NAD+ pool was sufficient to increase regeneration following
Fig 5. Dystrophin deficiency increased fibronectin in soleus muscles compared to healthy muscles.
A-C) Representative 10x immunohistochemical images for fibronectin (red) and DAPI (blue). All images have
been uniformly brightened to make the fibronectin signal easier to see. D) The percent positive pixels were
quantified. * indicates significantly different from C57. Width of white bar represents 100 microns. C57 (n = 7)
mdx (n = 6) mdxQ (n = 6).
doi:10.1371/journal.pone.0168293.g005
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cardiotoxin injection in dystrophic muscle [40]. Hence, we propose that the combination of
quercetin, to increase SIRT1 activity, and nicotinamide riboside, to increase muscle NAD
+ content in order to sustain increased SIRT1 activity, may provide long term therapeutic
relief and greater impact than either approach applied independently and may overcome limi-
tations in SIRT1 activation caused by age and/or disease severity.
Given the largely unremarkable histological and biochemical findings in this investigation,
one of the most notable findings in the current study was the quercetin-mediated elevations in
spontaneous activity in caged mice. It is unclear if quercetin directly impacts behavior such
Fig 6. Fiber area distribution is altered by dystrophin deficiency in soleus muscle. A-C) Representative 10x images from an
immunohistological experiment where laminin (red) was detected. DAPI is shown in blue. D) Fiber area distribution was measured and
quantified in bins. E) Mean fiber area and F) the variance coefficient were calculated. G) We also determined the percent of fibers
greater than the mean cross sectional area as another indicator of fiber area variability. * indicates significantly different from C57.
Width of white bar represents 100 microns. C57 (n = 7) mdx (n = 6) mdxQ (n = 6).
doi:10.1371/journal.pone.0168293.g006
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Table 2. Transcript expression in the soleus. Data are shown as fold change relative to C57. * indicates significantly different from C57; # indicates signifi-
cantly different from mdx. C57 (n = 7) mdx (n = 6) mdxQ (n = 6).
C57 Mdx mdxQ
Average ± SEM Average ± SEM Average ± SEM
Mitochondrial Biogenesis (PGC-1α Pathway Genes)
Sirt1 1.00 ± 0.25 2.02 ± 0.45 1.94 ± 0.54
Ppargc1a (Pgc-1α) 1.00 ± 0.11 -1.67 ± 0.09* -1.72 ± 0.09*
Esrra (Errα) 1.00 ± 0.18 -3.47 ± 0.11* -2.65 ± 0.06*
Nrf1 1.00 ± 0.23 -1.93. ± 0.11 -1.24 ± 0.28
Nrip1 1.00 ± 0.18 -1.45 ± 0.20 -1.46 ± 0.21
Tfam 1.00 ± 0.48 -1.34 ± 0.16 -2.07 ± 0.11
Metabolic Genes
Fnip1 1.00 ± 0.25 -1.84 ± 0.06 -2.08 ± 0.04
Mtor 1.00 ± 0.27 -2.48 ± 0.12* -2.57 ± 0.10*
Prkaa1 1.00 ± 0.16 -1.05 ± 0.14 -1.72 ± 0.12
Gapdh 1.00 ± 0.20 -3.48 ± 0.04* -2.97 ± 0.04*
Pfkm 1.00 ± 0.16 -2.38 ± 0.04* -2.38 ± 0.06*
Pparg 1.00 ± 0.19 -1.32 ± 0.27 -1.18 ± 0.40
Cs 1.00 ± 0.16 -3.64 ± 0.05* -3.60 ± 0.04*
Mdh1 1.00 ± 0.15 -1.94 ± 0.07* -2.27 ± 0.08*
Atp1a2 1.00 ± 0.07 -1.76 ± 0.10* -2.09 ± 0.06*
Cybb 1.00 ± 0.30 -1.35 ± 0.03 2.77 ± 1.35
Cycs 1.00 ± 0.27 1.11 ± 0.29 -2.45 ± 0.11
Mb 1.00 ± 0.17 -4.35 ± 0.03* -4.61 ± 0.04*
Mt-atp6 1.00 ± 0.07 -2.14 ± 0.05* -2.38 ± 0.06*
Mt-co1 1.00 ± 0.17 -2.78 ± 0.04* -3.18 ± 0.05*
Mt-co2 1.00 ± 0.14 -2.15 ± 0.07* -2.50 ± 0.06*
Mt-cyb 1.00 ± 0.09 -2.35 ± 0.04* -2.59 ± 0.06*
Mt-nd1 1.00 ± 0.06 -2.32 ± 0.04* -2.66 ± 0.06*
Mt-nd4 1.00 ± 0.21 -2.32 ± 0.05* -2.85 ± 0.06*
Uqcrc1 1.00 ± 0.17 -2.01 ± 0.09* -2.59 ± 0.05*
Tfb1m 1.00 ± 0.66 -1.49 ± 0.26 -2.95 ± 0.06
Tfb2m 1.00 ± 0.13 -2.50 ± 0.09* -1.70 ± 0.16
Ucp3 1.00 ± 0.21 -3.50 ± 0.11* -4.50 ± 0.04*
Ak1 1.00 ± 0.35 -2.68 ± 0.12 -2.18 ± 0.27
Akt1 1.00 ± 0.56 -4.43 ± 0.07 -2.97 ± 0.11
Ckm 1.00 ± 0.15 -1.87 ± 0.08 -1.92 ± 0.10
Inflammation/antioxidant Genes
NfKB1 1.00 ± 0.24 -1.35 ± 0.31 -1.10 ± 0.40
Il1b 1.00 ± 0.28 -1.23 ± 0.21 -2.55 ± 0.02
Tlr4 1.00 ± 0.61 -2.18 ± 0.19 -3.56 ± 0.06
Traf2 1.00 ± 0.16 -1.02 ± 0.40 1.23 ± 0.32
Cat 1.00 ± 0.51 -5.53 ± 0.03* -4.96 ± 0.06*
Gpx1 1.00 ± 0.47 -2.27 ± 0.17 -3.64 ± 0.07
Gpx4 1.00 ± 0.31 -2.29 ± 0.09* -2.69 ± 0.05*
Gsr 1.00 ± 0.29 2.02 ± 0.93 -1.25 ± 0.17
Nfe2l2 1.00 ± 0.15 -1.98 ± 0.13* -2.11 ± 0.13*
Prdx2 1.00 ± 0.25 -2.96 ± 0.06* -4.00 ± 0.04*
Sod1 1.00 ± 0.40 -2.36 ± 0.10 -3.37 ± 0.05*
(Continued)
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that it serves to stimulate activity via mechanisms beyond the scope of this investigation [41]
or below our detection threshold, or if quercetin supports improved function such that it per-
mits increased spontaneous activity. Nevertheless, that there was increased spontaneous physi-
cal activity provides an alternative interpretation of data contained herein. Increased physical
activity may hasten the decline of dystrophic muscle [42–44]; hence, improved specific tension
in the face of increased activity supports the potential therapeutic role of quercetin. This effect
seems particularly profound in the diaphragm as increased spontaneous physical activity led to
significantly impaired diaphragmatic function in animals of similar age [11]. Hence, that respi-
ratory and diaphragmatic function and histopathology were not further impaired compared to
untreated mdx mice in our previous investigation [25] may also be suggestive of a therapeutic
success. These histopathological results were largely recapitulated in limb muscle in this
Table 2. (Continued)
C57 Mdx mdxQ
Average ± SEM Average ± SEM Average ± SEM
Sod2 1.00 ± 0.25 -2.64 ± 0.05* -2.88 ± 0.06*
Apoptosis Genes
Apaf1 1.00 ± 0.27 -1.03 ± 0.07 1.68 ± 0.68
Bax 1.00 ± 0.37 1.12 ± 0.22 1.16 ± 0.28
Bcl2 1.00 ± 0.13 -1.59 ± 0.18 -1.63 ± 0.22
Bnip2 1.00 ± 0.17 -2.45 ± 0.08* -1.29 ± 0.12*#
Casp3 1.00 ± 0.44 -1.29 ± 0.33 -2.10 ± 0.18
Trp53 1.00 ± 0.33 -2.97 ± 0.14 -1.19 ± 0.47
Xiap 1.00 ± 0.27 -2.05 ± 0.12 -1.92 ± 0.12
Muscle Repair and Protein Turnover Genes
Fbl 1.00 ± 0.35 -1.48 ± 0.21 -1.15 ± 0.26
Gata2 1.00 ± 0.60 -2.16 ± 0.19 -3.78 ± 0.12
Hspa1a 1.00 ± 0.87 -1.88 ± 0.03 -2.47 ± 0.02
Hspa5 1.00 ± 0.36 -2.60 ± 0.07* -1.97 ± 0.11
Hspb1 1.00 ± 0.21 -1.33 ± 0.18 -1.99 ± 0.11*
Mef2c 1.00 ± 0.17 -1.96 ± 0.09* -2.68 ± 0.03*
Mstn 1.00 ± 0.26 -1.35 ± 0.19 -1.20 ± 0.21
Myf5 1.00 ± 0.38 -3.32 ± 0.08 -1.39 ± 0.38
Myocd 1.00 ± 0.26 -1.77 ± 0.33 -1.13 ± 0.71
Myod1 1.00 ± 0.67 -1.33 ± 0.53 -2.48 ± 0.15
Myof 1.00 ± 0.58 -2.06 ± 0.19 -2.39 ± 0.15
Myog 1.00 ± 0.59 -2.24 ± 0.17 -4.87 ± 0.07
Poldip2 1.00 ± 0.16 -1.24 ± 0.17 -2.11 ± 0.03*
Tgfb1 1.00 ± 0.10 1.45 ± 0.47 2.10 ± 1.00
Structural and Sarcomeric Genes
Dag1 1.00 ± 0.10 -1.53 ± 0.13* -2.27 ± 0.07*
Dtna 1.00 ± 0.16 -1.43 ± 0.08 -1.40 ± 0.12
Dysf 1.00 ± 0.16 -1.40 ± 0.15 -1.58 ± 0.10
Myh1 1.00 ± 0.39 -1.22 ± 0.15 -1.78 ± 0.05
Myh2 1.00 ± 0.17 -3.24 ± 0.04* -3.29 ± 0.06*
Myh7 1.00 ± 0.17 -2.56 ± 0.05* -2.92 ± 0.09*
Sgca 1.00 ± 0.17 -2.74 ± 0.05* -3.49 ± 0.06*
Utrn 3’ 1.00 ± 0.24 -1.15 ± 0.15 -1.32 ± 0.22
Utrn 5’ 1.00 ± 0.15 -1.54 ± 0.14 -1.17 ± 0.32
doi:10.1371/journal.pone.0168293.t002
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investigation, aside from the potential of increased fibrosis detected via trichrome staining but
not fibronectin immunohistochemistry. Given this integrated understanding from an estab-
lished model of DMD, the current findings may be all the more important in the eventual
translation of findings to clinical populations.
Comprehensive reports comparing dystrophic and healthy muscle from old animals, as per-
formed currently, are rarely reported in the existing literature [45]. Absolute and relative mus-
cle mass was increased in dystrophic muscle compared to age-matched C57 mice suggestive of
pseudohypertrophy. Further, tetanic force was similar between groups but specific tension was
greatly impaired in both the soleus and EDL at the end of the treatment periods indicating a
compromised muscle quality in mdx mice. Consistent with previous reports, in dystrophic
mice the soleus had compromised resistance to fatigue [43] and the EDL was more susceptible
to contraction-induced injury compared to control [2]. Histologically, the dystrophic soleus
had damage consistent with dystrophinopathy including increased centralized nuclei, necrotic
Fig 7. Relative protein abundance was altered by dystrophin deficiency. A) Protein abundance of
PGC-1α pathway components was largely depressed by dystrophin deficiency independent of intervention
compared to muscle from C57 mice. B) Representative blots are included and Ponceau S stain is included to
demonstrate equal loading. * indicates significantly different from C57. C57 (n = 5) mdx (n = 6) mdxQ (n = 5).
doi:10.1371/journal.pone.0168293.g007
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area, immune cell infiltration, and fibrosis [46, 47]. Fiber area distribution was also consistent
with dystrophin deficiency with a large proportion of small diameter fibers and much higher
variability in fiber size resulting in similar mean fiber area compared to control [48]. Our bio-
chemical evaluation found decreased transcript expression related to mitochondrial biogene-
sis, mitochondrial content, resistance to oxidative stress, and cellular stability.
In total, the results of this investigation are in agreement with our previous report of age-
dependent quercetin insensitivity leading to underwhelming therapeutic effects by the conclu-
sion of the study period. Specifically, quercetin insensitivity is made clear by a failure to increase
SIRT1 activity and may be due to decreased ATP and/or NAD+ content in dystrophic muscle.
Future investigations should combine quercetin with an agent to increase the NAD+ pool in
order to maximize therapeutic benefits. Furthermore, this study underscores the importance of
long-term investigations as therapeutics applied to the DMD community would be expected to
be employed for years. Only after 8 months of treatment was the transient therapeutic nature of
quercetin apparent in respiratory function [25]. Given the histological and biochemical data
from the soleus improved function will likely be lost with advancing age. Data interpretation is
complicated by our finding of increased spontaneous activity in quercetin-treated mice without
widespread activity-induced tissue damage in the limb muscles. This latter finding highlights a
novel experimental facet of this investigation and may hold implications for clinical translation.
Supporting Information
S1 Table. Complete Data Set. Individual mouse data for all measures including muscle func-
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